Pfizer Inc. (PFE)
Pfizer delivers mixed results for Q1, expands cost-cutting program
Pfizer Inc (NYSE:PFE, ETR:PFE) reported mixed results for the first quarter, including an earnings beat but revenue below expectations. Revenue fell 8% from the year-ago quarter to $13.7 billion, below estimates of $14 billion.
Pfizer (PFE) Surpasses Q1 Earnings Estimates
Pfizer (PFE) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.82 per share a year ago.
If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today
Few would dispute that Pfizer (PFE 0.63%) is an icon within the pharmaceutical world. And, giving credit where it's due, the drugmaker largely led the charge against the COVID-19 pandemic with both a vaccine and treatment.
Pfizer expands cost cuts, tops quarterly profit estimates even as sales fall
Pfizer expanded its cost-cutting efforts and reported first-quarter profit that topped estimates, even as the company's sales fell, largely due to dwindling Covid revenue. The cuts aim to help the pharmaceutical giant recover from the rapid decline of its Covid business and stock price over the last few years, and appear to be paying off.
Pfizer: I Am Locking In A 7.5% Dividend Yield Before Earnings
Pfizer's Q1 earnings release is a prime opportunity to secure about a 7.55% dividend yield, with revenue stabilizing post-pandemic and strong cost efficiency. Pfizer's robust product pipeline and consistent R&D investments position it well for future growth, despite past revenue volatility from COVID-19. Valuation metrics indicate Pfizer stock is significantly undervalued, with crucial ratios like Price/Book and Price/Cash Flow much lower than industry averages.
Will Pfizer's Non-COVID Drugs Drive Sales Again This Earnings Season?
Pfizer's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030
Pfizer (PFE) has been a behemoth in pharmaceuticals and drug development for decades, but lately has run into headwinds from vaccine sales, patent expiry, and more.
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Are Investors Undervaluing Pfizer (PFE) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Curious about Pfizer (PFE) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
Pfizer Stock Before Q1 Earnings Release: To Buy or Not to Buy?
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the first quarter.
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
